DocWire News Editors

DocwireNews

Cardiovascular benefits in patients with type 2 diabetes from the use of<a href="https://www.docwirenews.com/abstracts/cardiology-abstracts/dapagliflozin-cardiomyopathy-sodium-glucose-cotransporter-inhibitor/"> sodium-glucose cotransporter 2</a> (SGLT-2) inhibitors extend to all patient subgroups, according to results of a large meta-analysis published in the <a href="https://www.ahajournals.org/doi/10.1161/JAHA.119.014908">Journal of the American Heart Association</a>.The researchers included four large-scale clinical trials in the analysis. Each study looked at patients with diabetes mellitus and that reported overall cardiovascular outcomes (and for studies that defined patient subgroups by cardiovascular disease, kidney function, and heart failure). The total patient population between the included studies consisted of 38,723 patients with type 2 diabetes and treated with either canagliflozin, empagliflozin, and/or dapagliflozin. The authors used fixed effects models with inverse variance weighting to estimate summary hazard ratios (all confidence intervals were 95%).<h2>Benefits Across All Subgroups</h2>According to the results, there were 3,828 major adverse cardiac events reported. In the studies, 22,870 (59%) had cardiovascular disease, 7,754 (20%) had reduced kidney function, and 4,543 (12%) had heart failure. The overall reported benefit (expressed via hazard ratio) for major adverse cardiac events was 0.88; 95% CI, 0.83 to 0.94; P&lt;0.001). There was no evidence that the effects of the SGLT-2 inhibitor effect varied cross patient subgroups, and all patient subgroups showed some benefit with respect to hospitalization for heart failure, <a href="https://www.docwirenews.com/abstracts/cardiology-abstracts/lipoprotein-a-reduction-cardiovascular-disease/">cardiovascular</a> death, and any-cause mortality. Stroke showed a slight difference in the subgroups, with a protective effect observed in patients with reduced kidney function, but not in those with preserved kidney function.&ldquo;In this meta-analysis of large event-driven SGLT2 inhibitor outcome trials we found SGLT2 inhibitors protected against cardiovascular disease and death in diverse subsets of patients with type 2 diabetes regardless of their cardiovascular disease history,&rdquo; said Dr. Clare Arnott, lead study author and Senior Research Fellow at the George Institute for Global Health, said in a press <a href="https://www.eurekalert.org/pub_releases/2020-01/gifg-dcp013020.php">release</a>. &ldquo;While the extent of this protective effect may vary across patient types, the consistency of the findings suggests significant and broad cardiovascular protection can be achieved from use of this drug class.&rdquo;

Bradley Marder, MD

Joel M. Topf, MD, FACP

Gout Studies: Transplant Waitlisting and Bone Erosion

NKF Spring Clinical Meetings 2025

Jayme Locke, MD, MPH

The Promise of Xenotransplantation

Leah Lawrence

Real-World Data Backs Invasive DFS as Surrogate Endpoint for OS in EBC

HR Breast Cancer

Latest News

SGLT-2 Inhibitors Provide CV Benefits for All Type 2 Diabetics: Analysis

Cardiology

Cardiovascular benefits in patients with type 2 diabetes from the use of sodium-glucose cotransporter 2 (SGLT-2) inhibitors extend to all patient subgroups, according to ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe